Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma

Journal of Asthma

Volumn 40, Issue 4, 2003, Pages 383-393

  Schmier, Jordana ^a   Leidy, Nancy Kline ^a   Gower, Richard ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Rockwood Clinic   (United States)

Author keywords

Asthma; Clinical trial; Corticosteriod; Drug treatment; Health outcomes; Health related quality of life; Quality of life; SF 36; Symptoms

Indexed keywords

MOMETASONE FUROATE; PREDNISOLONE;

ARTICLE; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRY POWDER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; POWDERS; PREGNADIENEDIOLS; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 0037825836     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-120018708     Document Type: Article

References (35)

1. National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program, Expert Panel Report 2. US Department of Health and Human Services; 1997. Available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (accessed September 2001).
2. Apter AJ, Reisine ST, Affleck G, Barrows E, ZuWallack RL. The influence of demographic and socioeconomic factors on health-related quality of life in asthma. J Allergy Clin Immunol 1999; 103(1 Pt 1):72-78.
3. Bousquet J, Knani J, Dhivert H, Richard A, Chicoye A, Ware JE Jr, Michel FB. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med 1994; 149(2 Pt 1):371-375.
4. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47(2):76-83.
5. Marks GB, Dunn SM, Woolcock AJ. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol 1992; 45(5):461-472.
6. Schmier JK, Chan KS, Leidy NK. The impact of asthma on health-related quality of life. J Asthma 1998; 35(7):585-597.
7. Moy ML, Israel E, Weiss ST, Juniper EF, Dube L, Drazen JM. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med 2001; 163(4):924-929.
8. Viramontes JL, O'Brien B. Relationship between symptoms and health-related quality of life in chronic lung disease. J Gen Intern Med 1994; 9(1):46-48.
9. Aas K. Heterogeneity of bronchial asthma. Sub-populations - or different stages of the disease. Allergy 1981; 36(1):3-14.
10. Global Initiative for Asthma. Global strategy for asthma management and prevention NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung, and Blood Institute; Bethesda, MD. 1995; 95-3659. Available at http://www.ginasthma.com.
11. Perpina M, Belloch A, Marks GB, Martinez-Moragon E, Pascual LM, Compte L. Assessment of the reliability, validity, and responsiveness of a Spanish asthma quality of life questionnaire. J Asthma 1998; 35(6):513-521.
12. Cai B, Blais L, Suissa S, Ernst P. Distribution of asthma severity and change in severity over time in a general population. Am J Respir Crit Care Med 1999; 159(3):A133.
13. Leone FT, Grana JR, McDermott P, MacPherson S, Hanchak NA, Fish JE. Pharmaceutically-based severity stratification of an asthmatic population. Respir Med 1999; 93(11):788-793.
14. Osborne ML, Vollmer WM, Linton KL, Buist AS. Characteristics of patients with asthma within a large HMO: a comparison by age and gender. Am J Respir Crit Care Med 1998; 157(1):123-128.
15. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12(6):1322-1326.
16. Fireman P. Combination of inhaled corticosteroids plus other medications in the management of moderate to severe persistent asthma. Allergy Asthma Proc 2000; 21(5):315-322.
17. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52(Suppl 39)(39):1-34.
18. Bernstein DI, Berkowitz RB, Chervinsky P, Dvorin DJ, Finn AF, Gross GN, Karetzky M, Kemp JP, Laforce C, Lumry W, Mendelson LM, Nelson H, Pearlman D, Rachelefsky G, Ratner P, Repsher L, Segal AT, Selner JC, Settipane GA, Wanderer A, Cuss FM, Nolop KB, Harrison JE. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999; 93(9):603-612.
19. Noonan M, Karpel JP, Bensch GW, Ramsdell JW, Webb DR, Nolop KB, Lutsky BN. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001; 86(1):36-43.
20. Nathan RA, Nayak AS, Graft DF, Lawrence M, Picone FJ, Ahmed T, Wolfe J, Vanderwalker ML, Nolop KB, Harrison JE. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001; 86(2):203-210.
21. Nayak AS, Banov C, Corren J, Feinstein BK, Floreani A, Friedman BF, Goldsobel A, Gottschlich G, Hannaway PJ, Lampl KL, Lapidus RJ, Lawrence M, Lumry W, Muck Z, Pearlman D, Scardella A, Schenkel EJ, Sega AT, Segall N, Silverman B, Schneyer L, Nolop KB, Harrison JE. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000; 84:417-424.
22. Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-tomoderate persistent asthma. J Allergy Clin Immunol 2000; 106(3):485-492.
23. Fish JE, Karpel JP, Craig TJ, Bensch GW, Noonan M, Webb DR, Silverman B, Schenkel EJ, Rooklin AR, Ramsdell JW, Nathan R, Leflein JG, Grossman J, Graft DF, Gower RG, Garay SM, Frigas E, Degraff AC, Bronsky EA, Bernstein DI, Berger W, Shneyer L, Nolop KB, Harrison JE. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000; 106(5 Pt 1):852-860.
24. Nelson HS, Busse WW, deBoisblanc BP, Berger WE, Noonan MJ, Webb DR, Wolford JP, Mahajan PS, Hamedani AG, Shah T, Harding SM. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 1999; 103(2 Pt 1):267-275.
25. Noonan M, Chervinsky P, Busse WW, Weisberg SC, Pinnas J, de Boisblanc BP, Boltansky H, Pearlman D, Repsher L, Kellerman D. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152 (5 Pt 1):1467-1473.
26. Okamoto LJ, Noonan M, DeBoisblanc BP, Kellerman DJ. Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Ann Allergy Asthma Immunol 1996; 76(5):455-461.
27. Ware J, Kosinski M, Keller SD. SF-36 Physical and Mental Component Summary Scales: A User's Manual. Boston: The Health Institute, New England Medical Center, 1994.
28. Ware JEJ, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993.
29. Mahajan P, Okamoto LJ, Schaberg A, Kellerman D, Schoenwetter WF. Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma. J Asthma 1997; 34(3):227-234.
30. Marks GB, Dunn SM, Woolcock AJ. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma [see comments]. J Clin Epidemiol 1993; 46(10):1103-1111.
31. Katz PP, Eisner MD, Henke J, Shiboski S, Yelin EH, Blanc PD. The Marks asthma quality of life questionnaire: further validation and examination of responsiveness to change. J Clin Epidemiol 1999; 52(7):667-675.
32. Marks GB, Heslop W, Yates DH. Prehospital management of exacerbations of asthma: relation to patient and disease characteristics. Respirology 2000; 5(1):45-50.
33. Premaratne UN, Sterne JA, Marks GB, Webb JR, Azima H, Burney PG. Clustered randomised trial of an intervention to improve the management of asthma: Greenwich asthma study. BMJ 1999; 318(7193):1251-1255.
34. Ware JE Jr, Kemp JP, Buchner DA, Singer AE, Nolop KB, Goss TF. The responsiveness of disease-specific and generic health measures to changes in the severity of asthma among adults. Qual Life Res 1998; 7(3):235-244.
35. van der Molen T, Sears MR, de Graaff CS, Postma DS, Meyboom-de Jong B. Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators. Eur Respir J 1998; 12(1):30-34.